Navigation Links
NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
Date:11/8/2012

LAWRENCE, Mass., Nov. 8, 2012 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported record financial results for the third quarter ended September 30, 2012, with total revenue above the top end of its guidance range. 

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

Revenue for the third quarter of 2012 increased 9% to $61.2 million, compared with revenue of $55.9 million for the third quarter of 2011.  The higher revenues were driven by increased adoption of the NxStage System One™.

Home revenue for the third quarter of 2012 increased 17% to a record $31.9 million compared with revenues of $27.2 million for the third quarter of 2011. 

"Home growth remains strong," commented Jeffrey H. Burbank, Founder and Chief Executive Officer. "We continue to deliver double digit growth because we're doing the right thing for patients.  We remain committed to increasing adoption of home, more frequent dialysis, and see multiple catalysts for growth including; increased patient demand, our robust product portfolio and our centers of excellence strategy.  With continued execution, we believe we can achieve over 14% annual growth in the Home for 2012."

Critical Care revenue decreased slightly to $9.1 million for the third quarter of 2012 compared with revenues of $9.2 million for the third quarter of 2011 reflecting equipment purchasing delays by hospitals.  Revenue in the In-Center market was $19.6 million for the third quarter of 2012. 

NxStage reported a net loss of $2.6 million or $(0.04) per share for the third quarter of 2012 compared with a net loss of $5.3 million or $(0.10) per share for the third quarter of 2011.For the third quarter of 2012, the Company reported Adjusted EBITDA, adjusted for stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses, of $2.4 million compared with $2.4 million for the third quarter of 2011.  (See the exhibits for a reconciliation of this non-GAAP measure.)

Guidance:

"For the full fiscal year 2012, the Company is narrowing its guidance range to reflect the impact of lengthened hospital capital budget cycles with respect to equipment sales within the Company's critical care business as well as lower international equipment sales in the fourth quarter of 2012 and approximately $2 million in annual dialyzor production revenue versus our earlier projections of $3-4 million.  We expect our new manufacturing plant in Germany to be fully operational by the end of Q4 and believe this relationship will provide us with long-term cost efficiencies through increased dialyzer production volumes," stated Robert Brown, Chief Financial Officer.

For the full fiscal year 2012, the Company now expects revenue to be the range of $240 million and $242 million, a net loss in the range of $15.3 to $16.3 million, or $(0.26) to $(0.28) per share and for Adjusted EBITDA to be in the range of $8.0 million to $9.0 million compared with its previous guidance for full year 2012 revenue to be between $240 million and $245 million, a net loss in the range of $14.0 to $18.0 million or ($0.25) to ($0.32) per share and for Adjusted EBITDA to be in the range of $8.0 million to $12.0 million.

For the fourth quarter of 2012, the Company is forecasting revenues to be between $63.0 million and $65.0 million, a net loss in the range of $2.5 million to $3.5 million, or $(0.04) to $(0.06) per share, and Adjusted EBITDA in the range of $2.0 million to $3.0 million. 

This release contains a non-GAAP financial measure.  A reconciliation of the Company's non-GAAP financial measure to its most comparable GAAP financial measure is in the exhibits to this press release.

Conference Call:NxStage will also host a conference call today, Thursday, November 8, 2012 at 9:00 a.m. Eastern Time to discuss its third quarter financial results. To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international).  The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at www.nxstage.com.

A replay of the conference call will be available 2 hours after the completion of the call through November 15, 2012.  To access the replay dial 855- 859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 39189975.  An online archive of the conference call can be accessed via the investor relations section of the Company's website at www.nxstage.com.

About NxStageNxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin and Adjusted EBITDA numbers, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Inc. and Fresenius Medical Care, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.Contact:Kristen K. Sheppard, Esq.VP, Investor Relationsksheppard@nxstage.comNon-GAAP Financial Measure

The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States and may be different from similar non-GAAP financial measures used by other companies. The non-GAAP financial measure disclosed by the Company is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. Management uses Adjusted EBITDA (EBITDA adjusted for stock based-compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses) to understand operational cash usage.  The Company believes the non-GAAP financial measure provides useful and supplementary information allowing investors greater transparency to one measure used by management.  The non-GAAP financial measure is meant to supplement, and to be viewed in conjunction with, GAAP financial measures.  The non-GAAP financial measure is reconciled to the most comparable GAAP financial measure below.

 

 

NxStage Medical, Inc.Condensed Consolidated Statements of Comprehensive Loss(in thousands, except per share data)(unaudited) Three Months Ended
September 30,Nine Months Ended
September 30,2012201120122011Revenues

$

61,152$

55,903$

177,112$

160,235Cost of revenues

37,40436,363109,663103,797Gross profit

23,74819,54067,44956,438Operating expenses:Selling and marketing

10,1689,44630,00628,025Research and development

4,2743,38812,42110,694Distribution

4,7314,70913,84513,298General and administrative

6,9215,70820,47316,750Total operating expenses

26,09423,25176,74568,767Loss from operations

(2,346)(3,711)(9,296)(12,329)Other expense:Interest expense

(26)(1,186)(2,675)(3,513)Other income (expense), net

13(146)(118)(342)(13)(1,332)(2,793)(3,855)Net loss before income taxes

(2,359)(5,043)(12,089)(16,184)Provision for income taxes

223235700654Net loss

$

(2,582)$

(5,278)$

(12,789)$

(16,838)Net loss per share, basic and diluted

$

(0.04)$

(0.10)$

(0.22)$

(0.31)Weighted-average shares outstanding, basic and diluted

58,94554,42857,48253,953Other comprehensive loss:Foreign currency gain (loss)

$

164$

(232)$

64$

72Other gain (loss)

547(17)523(11)Comprehensive loss

$

(1,871)$

(5,527)$

(12,202)$

(16,777) 

 

 

NxStage Medical, Inc.Condensed Consolidated Balance Sheets(in thousands, except share data)(unaudited) September 30,December 31,20122011ASSETSCurrent assets:Cash and cash equivalents

$

102,679$

102,909Accounts receivable, net

19,58815,808Inventory

34,87932,775Prepaid expenses and other current assets

1,8952,777Total current assets

159,041154,269Property and equipment, net

33,71617,599Field equipment, net

10,14312,182Deferred cost of revenues

38,39141,132Intangible assets, net

20,51822,615Goodwill

42,69842,698Other assets

3,0491,213Total assets

$

307,556$

291,708LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$

14,812$

15,634Accrued expenses

19,33715,165Other current liabilities

669—Total current liabilities

34,81830,799Deferred revenues

53,56557,014Long-term debt

—43,235Other long-term liabilities

21,3769,474Total liabilities

109,759140,522Commitments and contingenciesStockholders' equity:Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized;  no shares issued and outstanding as of September 30, 2012 and December 31, 2011

——Common stock: par value $0.001, 100,000,000 shares authorized; 59,628,194 and 56,167,090 shares issued as of September 30, 2012 and December 31, 2011, respectively

5956Additional paid-in capital

549,387489,542Accumulated deficit

(342,617)(329,828)Accumulated other comprehensive income (loss)

519(68)Treasury stock, at cost: 541,584 and 480,923 shares as of September 30, 2012 and December 31, 2011, respectively

(9,551)(8,516)Total stockholders' equity

197,797151,186Total liabilities and stockholders' equity

$

307,556$

291,708 

 

NxStage Medical, Inc.Cash Flows from Operating Activities(in thousands)(unaudited) Nine Months Ended September 30,20122011Cash flows from operating activities:Net loss

$

(12,789)$

(16,838)Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Depreciation and amortization

17,49517,415Stock-based compensation

9,21310,166Other

3,0472,387Changes in operating assets and liabilities:Accounts receivable

(3,753)(3,414)Inventory

(11,638)(15,196)Prepaid expenses and other assets

(384)(2,067)Accounts payable

(863)2,296Accrued expenses and other liabilities

3,691195Deferred revenues

(3,449)1,316Net cash provided by (used in) operating activities

$

570$

(3,740) 

 

 

NxStage Medical, Inc.Revenues by Segment(in thousands)(unaudited) Three Months Ended
September 30,Nine Months Ended
September 30,2012201120122011System One segmentHome

$

31,925$

27,218$

92,171$

80,276Critical Care

9,0999,17028,25725,199Total System One segment

41,02436,388120,428105,475In-Center segment

19,63719,51555,47754,760Other

491—1,207—Total

$

61,152$

55,903$

177,112$

160,235 

 

NxStage Medical, Inc.Non-GAAP Financial Measures(in millions)(unaudited) Three Months Ended
September 30,Nine Months Ended
September 30,2012201120122011Net loss

$

(2.6)$

(5.3)$

(12.8)$

(16.8)Less: Depreciation, amortization, interest, and taxes

6.27.521.021.9Less: Adjusting items*

(1.2)0.2(2.3)0.2Adjusted EBITDA

$

2.4$

2.4$

5.9$

5.3* Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses 

 

NxStage Medical, Inc.Non-GAAP Financial Guidance(in millions)(unaudited) Three Months Ended
December 31, 2012High
EstimateLow
EstimateNet loss

$

(2.5)$

(3.5)Less: Depreciation, amortization, interest, and taxes

6.56.5Less: Adjusting items*

(1.0)(1.0)Adjusted EBITDA

$

3.0$

2.0* Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses 


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
2. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
3. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
4. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
6. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
7. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
8. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
9. Discovery Labs Reports Third Quarter 2012 Financial Results
10. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016   Change Healthcare , a ... solutions and technology-enabled services designed to enable ... a strategic channel partnership with SourceMed, the ... and revenue cycle management services that empower ... clinics to optimize revenue, operational efficiency and ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, ... Therawis bedient dringenden Bedarf ... QIAGEN N.V. (NASDAQ: QGEN ; ... Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur ... eingegangen zu sein. Ein erstes Projekt wird die ...
(Date:5/25/2016)... -- According to market research "Global Insulin ... Forecast to 2022 - Industry Insights by Type (Insulin ... P&S Market Research, the global insulin delivery device market ... is expected to grow at a CAGR of 6.6% ... is expected to witness the fastest growth at a ...
Breaking Medicine Technology:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... education and products recently hosted the first PowerWave Instructor Certification Course in Stoughton, ... lead a group of fitness professional through the 8 hour interactive course to ...
(Date:5/26/2016)... , ... May 26, 2016 , ... On May 23rd ... Research Water Life Science® and international water advocate, was honored by Ashram, Inc. as ... in ancient Egypt who knelt on the banks of the Nile to fill their ...
(Date:5/26/2016)... Ca (PRWEB) , ... May 26, 2016 , ... ... the organization to provide strategic sales leadership and to further develop their rapidly ... a B.S. in Business Administration with a concentration in Marketing and an M.B.A. ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... May 2016 ... been so central to popular cosmetic improvement efforts. Record numbers of clients now ask ... more prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... to serve on its Accreditation and Standards Committees and support the organization’s ... incorporate key process and outcome measures, with the ultimate mission of improving ...
Breaking Medicine News(10 mins):